On Saturday, Sept. 13, 2008, I should’ve been watching college football on television. I wasn’t. —Recommended Link— This Tiny Biotech Is Set To Disrupt A $133 Billion Market It’s like something straight out of science-fiction… According to our research, the U.S. Army has invested in a small biotech company with a breakthrough technology using the DNA of spiders. We’re not kidding. Not only could it change the future of warfare — it has a host of unique properties that could lead to a range of applications, allowing early investors to strike it rich. To get all the fascinating details,… Read More
On Saturday, Sept. 13, 2008, I should’ve been watching college football on television. I wasn’t. —Recommended Link— This Tiny Biotech Is Set To Disrupt A $133 Billion Market It’s like something straight out of science-fiction… According to our research, the U.S. Army has invested in a small biotech company with a breakthrough technology using the DNA of spiders. We’re not kidding. Not only could it change the future of warfare — it has a host of unique properties that could lead to a range of applications, allowing early investors to strike it rich. To get all the fascinating details, go here. I was glued to CNBC as the events unfolded surrounding whether or not Lehman Brothers, one of the nation’s largest and oldest investment banks, could be saved from failure. By Sunday, Sept. 14, all options were exhausted, and the news hit the tape that Lehman Brothers, after being in business for nearly 160 years, would file for bankruptcy and cease to exist as a viable entity. The markets braced for impact on the open Monday. “It’s gonna be bad.” I told my wife as I stared at the television. “Oh, you’ve said that before,” she replied. “No,” I… Read More